Adaptimmune Broadens Executive Team
(Thomson Reuters ONE) -
PHILADELPHIA and OXFORD, United Kingdom, March 15, 2017 (GLOBE NEWSWIRE) --
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat
cancer, today announced that it has broadened its executive team with the
appointment of co-founder, Helen Tayton-Martin, Ph.D., M.B.A, to the newly-
created role of Chief Business Officer, and Mr. William (Bill) Bertrand, Jr.,
J.D., as Chief Operating Officer. Both appointments are effective immediately.
Adaptimmune has an unrivalled portfolio of SPEAR T-cells, with four INDs open,
including three for its wholly-owned SPEAR T-cells. Adaptimmune is also
progressing pre-clinical work on a number of other targets, other HLA programs,
second-generation products, allogeneic cells and autoimmune disease, and has a
partnership with Bellicum to evaluate its switch technology.
Dr. Tayton-Martin has transitioned from her prior role as COO to the new CBO
position that will see her focus entirely on optimizing the strategic and
commercial opportunity for the Company's assets. Her new role encompasses all
aspects of pipeline and technology assessment, strategic portfolio analysis,
partnerships and commercial planning. She will retain responsibility for
alliances including the strategic partnership with GSK.
Mr. Bertrand, a highly experienced senior leader within the U.S. biotech
industry, will assume responsibility for a range of operational functions,
including compliance, risk management, human resources and legal/IP, based at
Adaptimmune's U.S. headquarters in Philadelphia. Mr. Bertrand will work closely
with Dr. Tayton-Martin and the rest of the executive team in helping to prepare
Adaptimmune for its next stage of development.
"We are delighted to welcome Bill Bertrand on board. Having been a senior
executive at numerous life sciences companies, he brings extensive operational
and management experience that is invaluable to support our next development
stage, and, importantly, this appointment will also enable Helen Tayton-Martin
to focus exclusively on maximizing the commercial opportunity for our
substantial pipeline," said James Noble, Adaptimmune's Chief Executive Officer.
"This is a very exciting time for Adaptimmune as we progress four INDs enabling
nine studies across 11 indications. I am pleased to be able to focus entirely on
strategically optimizing our portfolio and partnerships," commented Dr. Tayton-
Martin.
"I am enthusiastic about joining Adaptimmune," said Mr. Bertrand. "I believe the
Company has great potential and it has already achieved numerous key milestones,
with a very exciting future in prospect. I look forward to working with James
and the rest of the team as we continue to build Adaptimmune for its next stage
of growth and prepare for and deliver our pipeline to patients."
Dr. Tayton-Martin has 25 years of experience working within the pharma, biotech
and consulting environment in disciplines across preclinical and clinical
development, outsourcing, strategic planning, due diligence and business
development. She formerly served as Chief Operating Officer and is a co-founder
of Adaptimmune, joining from Avidex Limited (subsequently Medigene) where she
was responsible for commercial development of the soluble TCR program in cancer
and HIV therapy. Dr. Tayton-Martin holds a Ph.D. in molecular immunology from
the University of Bristol, U.K. and an M.B.A. from London Business School.
Mr. Bertrand's prior experience includes a 12 year tenure at MedImmune, where he
served as its first General Counsel and Chief Compliance Officer, along with
holding a variety of operational and corporate strategy roles. He has also
formerly served as Executive Vice President, General Counsel for Infinity
Pharmaceuticals, Inc., and as Senior Vice President, Acting Chief Operating
Officer and General Counsel for Salix Pharmaceuticals, where he remained as
General Manager to help finalize the integration of the company's $14 billion
acquisition by Valeant Pharmaceuticals in April 2015. He is currently a member
of the board of directors of Ardelyx, Inc. (Nasdaq:ARDX). Mr. Bertrand received
a J.D. from the University of Wisconsin and a B.S. in biology from Wayne State
University.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the
development of novel cancer immunotherapy products. The Company's unique SPEAR®
(Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the
engineering of T-cells to target and destroy cancer, including solid tumors.
Adaptimmune has a number of proprietary clinical programs, and is also
developing its NY-ESO SPEAR T-cell program under a strategic collaboration and
licensing agreement with GlaxoSmithKline. The Company is located in
Philadelphia, USA and Oxfordshire, U.K. For more information, please visit
http://www.adaptimmune.com
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking
statements involve certain risks and uncertainties. Such risks and uncertainties
could cause our actual results to differ materially from those indicated by such
forward-looking statements, and include, without limitation: the success, cost
and timing of our product development activities and clinical trials and our
ability to successfully advance our TCR therapeutic candidates through the
regulatory and commercialization processes. For a further description of the
risks and uncertainties that could cause our actual results to differ materially
from those expressed in these forward-looking statements, as well as risks
relating to our business in general, we refer you to our Annual Report on Form
10-K filed with the Securities and Exchange Commission (SEC) on March 13, 2017,
and our other SEC filings. The forward-looking statements contained in this
press release speak only as of the date the statements were made and we do not
undertake any obligation to update such forward-looking statements to reflect
subsequent events or circumstances.
Adaptimmune Contacts
Investor Relations
Will Roberts
T: (215) 825-9306
E: will.roberts(at)adaptimmune.com
Juli Miller, Ph.D.
T: (215) 825-9310
E: juli.miller(at)adaptimmune.com
Media Relations
Margaret Henry
T: +44 (0)1235 430036
Cell: +44 (0)7710 304249
E: margaret.henry(at)adaptimmune.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Adaptimmune Therapeutics plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 15.03.2017 - 12:30 Uhr
Sprache: Deutsch
News-ID 530410
Anzahl Zeichen: 7531
contact information:
Town:
Philadelphia
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 167 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Adaptimmune Broadens Executive Team"
steht unter der journalistisch-redaktionellen Verantwortung von
Adaptimmune Therapeutics plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
